Analyst Price Targets — LENZ
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| October 27, 2025 10:52 am | Matthew Caufield | H.C. Wainwright | $56.00 | $30.87 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on LENZ Therapeutics Inc (LENZ) |
| October 10, 2025 10:47 am | — | Piper Sandler | $67.00 | $46.25 | TheFly | Lenz Therapeutics price target raised to $67 from $51 at Piper Sandler |
| April 14, 2025 10:36 am | Biren Amin | Piper Sandler | $51.00 | $23.24 | TheFly | Lenz Therapeutics assumed with an Overweight at Piper Sandler |
| August 15, 2024 8:44 am | Joseph Catanzaro | Piper Sandler | $36.00 | $22.25 | StreetInsider | Piper Sandler Reiterates Overweight Rating on LENZ Therapeutics Inc (LENZ) |
| August 15, 2024 4:58 am | Yigal Nochomovitz | Citigroup | $32.00 | $23.50 | StreetInsider | LENZ Therapeutics Inc (LENZ) PT Lowered to $32 at Citi |
Latest News for LENZ
MHRA submission follows EMA validation of the VIZZ MAA in March 2026 Sixth ex-U.S. regulatory submission for VIZZ underscores accelerating global expansion SAN DIEGO, April 20, 2026 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ) today announced that it has submitted a Marketing Authorization Application (MAA) to the United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) for the…
LENZ Therapeutics offers a very high-risk but even higher-reward opportunity with Vizz, its aceclidine-based eye drop for presbyopia. I estimate a bit conservative base-case fair value of $25 per share, implying ~200% upside from current levels, driven by US and international partnerships. Key forward driver is Vizz refill rates, with management set to disclose actual refill percentages in H2; side effect fears…
It's recently commercialized VIZZ hasn't generated much fizz with the market yet. It has high hopes for the blurry vision treatment.
Abeona Therapeutics (NASDAQ: ABEO - Get Free Report) and LENZ Therapeutics (NASDAQ: LENZ - Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, profitability, valuation, analyst recommendations, institutional ownership and risk. Risk and Volatility Abeona Therapeutics has a
LENZ Therapeutics, Inc. (LENZ) Q4 2025 Earnings Call Transcript
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for LENZ.
U.S. House Trading
No House trades found for LENZ.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.